BAC and GE Healthcare will together develop and market affinity chromatography media for the purification of therapeutic recombinant Factor VIII.
BAC will provide its CaptureSelect® affinity ligands for process-scale purification of FVIII for the prevention and treatment of bleeding in patients with haemophilia A.